Scarica l'app Stockscreener
47.84
7.86%
3.45
Uniqure Nv Borsa (QURE) Ultime notizie
uniQure initiates $150 million public offering - The Pharma Letter
symbol__ Stock Quote Price and Forecast - CNN
uniQure commences $150 million public offering of shares - Investing.com UK
UniQure surges on plans to seek US nod for gene therapy - MSN
QURE: New Offering Managed by Leerink Partners and Stifel - GuruFocus
uniQure (QURE) Launches $150M Public Offering Amid After-Hours D - GuruFocus
uniQure (NASDAQ: QURE) seeks $150M in equity and pre-funded warrants ahead of AMT-130 BLA - Stock Titan
UniQure Announces Planned $150 Million Public Offering - marketscreener.com
uniQure commences $150 million public offering of shares By Investing.com - Investing.com Canada
uniQure starts $150M share sale, with $22.5M extra option - Stock Titan
uniQure Announces $150 Million Proposed Public Offering - GlobeNewswire
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Benzinga
uniQure (QURE) Secures FDA Reversal for Huntington's Disease Gen - GuruFocus
Form 8K uniQure N.V. For: 22 June By Investing.com - Investing.com India
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene TherapyRegenxbio (NASDAQ:RGNX) - Benzinga
Uniqure N.v. Insider Sold Shares Worth $9,371,612, According to a Recent SEC Filing - marketscreener.com
uniQure Reports Promising Preliminary Results for AMT-260 Gene Therapy in Refractory Mesial Temporal Lobe Epilepsy Phase I/IIa Trial 1 – Minichart - Minichart
uniQure (QURE) CEO sells 206,100 shares and exercises stock options - Stock Titan
Uniqure N.v. Insider Sold Shares Worth $526,485, According to a Recent SEC Filing - Moomoo
uniQure (QURE) director exercises 11,685 options, sells shares under 10b5-1 - Stock Titan
uniQure (QURE) director Jack Kaye sells shares after exercising stock options - Stock Titan
uniQure reports preliminary AMT-260 Phase I/IIa low-dose results; 3 of 6 patients show 79–100% seizure reduction - TradingView
uniQure (QURE) shows mixed but promising early AMT-260 MTLE results - Stock Titan
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
Technical Reactions to QURE Trends in Macro Strategies - Stock Traders Daily
uniQure reports mixed results from epilepsy gene therapy trial By Investing.com - Investing.com Australia
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval - Yahoo Finance
uniQure reports mixed results from epilepsy gene therapy trial - Investing.com UK
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now - InvestorPlace
uniQure’s epilepsy gene therapy showed seizure drops in 3 patients - Stock Titan
uniQure (QURE) Unveils Early Data on Gene Therapy for Epilepsy - GuruFocus
What Caused uniQure's Dramatic Stock Plunge - Kavout
uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy - Benzinga
QURE Maintained by Goldman Sachs -- Price Target Raised to $46 - GuruFocus
QURE Maintained by Leerink Partners -- Price Target Raised to $7 - GuruFocus
uniQure N.V. (NASDAQ: QURE) insider sells 164,429 shares across June filings - Stock Titan
QURE Upgraded by Barclays -- Price Target Raised to $65 - GuruFocus
Uniqure NV (QURE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting - Barchart.com
QURE Maintained by RBC Capital -- Price Target Raised to $65.00 - GuruFocus
UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says - marketscreener.com
uniQure receives FDA pathway for Huntington’s disease therapy - Investing.com UK
Worldwide Healthcare Trust PLCPortfolio Holding uniQure N.V. Announces Filing Plans with U.S. Food & Drug Administration - Sharecast.com
uniQure (QURE) Receives Upgrade from Barclays with Increased Pri - GuruFocus
uniQure receives FDA pathway for Huntington’s disease therapy By Investing.com - Investing.com South Africa
UniQure: AMT-130's FDA Path Reaffirms My Bull Case (NASDAQ:QURE) - Seeking Alpha
Barclays upgrades uniQure stock rating on Huntington’s timeline By Investing.com - Investing.com Australia
Barclays upgrades uniQure stock rating on Huntington’s timeline - Investing.com
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $46 to $70 - 富途牛牛
uniQure stock rating reiterated at Buy by H.C. Wainwright on FDA update - Investing.com
Leerink raises uniQure stock price target to $70 on FDA reversal By Investing.com - Investing.com South Africa
1.21%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):